Gilead CEO Daniel O'Day on acquisition of cancer drugmaker Immunomedics

Gilead Sciences will acquire biotech company Immunomedics in a $21 billion deal that will expand Gilead's availability of cancer treatments, the companies announced on Sunday. Daniel O'Day, Gilead chairman and CEO, joins "Squawk Box" to discuss.
Mon, Sep 14 20207:25 AM EDT